
Keywords: OAT; oral anticoagulation therapy; AF; atrial fibrillation; MACE; major adverse cardiac event; INR; international normalized ratio; VKA; vitamin K antagonist; RFCA; radiofrequency catheter ablation; TTR; target therapeutic range; NOACs; new oral anticoagu